Clinical observations suggest the importance of immune mechanisms in recovery from varicella-zoster virus (VZV) infections. Primary VZV infections may be severe in individuals with deficiencies in cellular immunity, although individuals with deficiencies in antibody production usually have no difficulty in handling infections. These observations suggest that cellular immunity is more important than humoral immunity in recovery from primary VZV infection (9). On the other hand, administration of large amounts of antibody to VZV in the form of zoster immune globulin may prevent or modify primary VZV infection (3). However, cellular immune mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), may play a role in this effect. Finally, reactivation infection (herpes zoster) tends to occur more frequently and to be more severe in certain immunocompromised individuals, but it is not known whether immune mechanisms contribute to prevention of reactivation infections.
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In vitro assays for cellular immunity to VZV have been developed for studies of host responses to VZV infections. VZV-specific lymphocyte proliferation has been widely used to assess cellular immunity (9). Lymphocyte-macrophage-mediated inactivation of VZV has also been described (4) but is a somewhat cumber-some assay for clinical studies. Cytotoxic activity against VZV-infected targets has been described, but the type of killing was not fully defined (11). Recently a preliminary report appeared on ADCC against target cells infected with VZV (Cross et al., Fed. Proc. 40:988, 1981) . In the present study we confirmed the existence of ADCC to VZV by using cryopreserved target cells, and we compared antibody titers detected in the ADCC assay to those obtained in the commonly used assay for fluorescent antibody to membrane antigen (FAMA; 12). were then incubated at 37°C in a 5% CO2 incubator for 1 h, during which time the tubes were gently agitated at intervals of about 15 min. The labeled target cells were washed four times with cold Hanks-balanced salt solution with 5% FCS and were suspended at a concentration of 5 x 104 cells per ml in RPMI 1640 with 20o FCS. Labeled target cells were distributed into round-bottomed microtiter plate wells (Flow Laboratories) with 5 x 103 cells per well in a volume of 0.1 ml.
Samples (10 RI) of appropriate dilutions of seropositive or seronegative individual sera or serum pools were added, and the plates were incubated for 30 min at 4°C.
Effector cell suspensions were added in 100-ILI portions to give the desired effector-to-target cell (E:T) ratios. Each determination was performed in triplicate. The microtiter plates were then centrifuged at room temperature for 3 min at 800 rpm to facilitate cell-to-cell contact and were then incubated for 4 h at 37°C in a 5% CO2 incubator. After incubation, 100 ,u of medium was removed from the top of each well with an Eppendorf pipette and was transferred to a counting tube. 51Cr release was counted in a gamma scintillation counter (LKB Wallac, Turku, Finland). Total releasable activity was determined by the addition of 1% Triton X-100. Spontaneous release from target cells was determined in the absence of effector cells. The percentage of 51Cr release in the presence of effector cells and either antibody-positive or antibodynegative serum was calculated as (counts per minute experimental release -counts per minute spontaneous release)/(counts per minute total release -counts per minute spontaneous release).
ADCC was defined as the percentage of 51Cr release in the presence of antibody-poJitive serum minus the percentage of 5tCr release in the presence of antibodynegative serum.
Determination of titer of ADCC antibodies against VZV. Twofold dilutions of test sera from 1:1 to 1:256 were prepared. Samples (10 ,ul) of each dilution were added in triplicate to the cytotoxicity assay as described above. The ADCC titer of a serum was defined as the reciprocal of the highest final serum dilution which resulted in 51Cr release which was more than two standard deviations above the mean 51Cr release detected in the presence of antibody-negative serum. (Fig. 1) . With higher E:T ratios, the magnitude of ADCC did not increase. E:T ratios of 50:1 were used in subsequent experiments.
RESULTS

Susceptibility of VZV-infected targets to ADCC. FS-4 cells infected with VZV for 24 to
Effect of donor immune status on ADCC. To determine whether immune status influenced the magnitude of ADCC, effector cells from seropositive and seronegative normal children were tested in the ADCC assay. The mean ages of the children in the two groups were similar: 4.8 years for the seronegative group and 4.5 years for the seropositive one. The magnitude of ADCC varied greatly among individuals in each group (Fig. 2) , but mean ADCC was not significantly different (P > 0.01 by Student's t test).
There was no correlation between age and the magnitude of ADCC (data not shown).
Determination of antibody titer by ADCC. The titers of 10 sera obtained from naturally seropositive donors were determined in the ADCC assay. ADCC usually declined with increasing serum dilutions, except for one serum which demonstrated an apparent prozone phenomenon (Fig. 3) . The percentage of cytotoxicity with pooled seronegative sera was 1.7 ± 1.6 in this experiment (data not shown). Therefore, the ADCC titer for each tested serum was the reciprocal of the highest dilution which produced 51Cr release of >4.9%, two standard deviations above the mean obtained with pooled seronegative sera. The 10 sera had the titers of 320 (2 sera), 1,280 (6 sera), and 5,120 (2 sera). Zoster immune globulin with a FAMA titer of 4,096 had a titer of 204,800 in the ADCC assay (data not shown).
Comparison of antibody titer by ADCC and FAMA assays. To determine the relative sensitivity of the ADCC and FAMA assays for detection of VZV antibodies, 40 sera from normal children or adults with no history of recent varicella were studied by both procedures (Fig.  4) . Sera with FAMA titers of <2 were also negative in the ADCC assay. All sera with FAMA titers of >2 were positive in the ADCC assay. Antibody titers determined by ADCC were frequently 5 to 20 times higher than those obtained by FAMA, and there was significant positive correlation between titers obtained in these two assays (r = 0.67, P < 0.005; Spearman rank correlation). DISCUSSION
The cytotoxic activity measured in our assay appears to be ADCC in view of the requirement for antibody and the ability of effector cells from seronegative as well as from seropositive donors to mediate the reaction. The detection of high titers of antibody in zoster immune globulin suggests that the antibody is largely of the immunoglobulin G class, although on the basis of our data we cannot rule out the participation of other immunoglobulin classes.
We Recently, Gershon and Steinberg have described inactivation of VZV by nonadherent peripheral blood mononuclear cells and antibody in a plaque reduction assay (5). This effect appeared to be due to the antibody-dependent killing of infected cells. Although the plaque reduction assay of Gershon and Steinberg and the 51Cr release assay described in the present paper may measure the same immunological function, the 51Cr release assay is easier to perform, particularly if large numbers of specimens are to be tested.
